AU2981992A - Expression of specific immunogens using viral antigens - Google Patents

Expression of specific immunogens using viral antigens

Info

Publication number
AU2981992A
AU2981992A AU29819/92A AU2981992A AU2981992A AU 2981992 A AU2981992 A AU 2981992A AU 29819/92 A AU29819/92 A AU 29819/92A AU 2981992 A AU2981992 A AU 2981992A AU 2981992 A AU2981992 A AU 2981992A
Authority
AU
Australia
Prior art keywords
expression
viral antigens
specific immunogens
immunogens
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29819/92A
Other languages
English (en)
Inventor
Paul Porwen Hung
Narender Kumar Kalyan
Shaw-Guang Lin Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU2981992A publication Critical patent/AU2981992A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU29819/92A 1991-12-11 1992-12-02 Expression of specific immunogens using viral antigens Abandoned AU2981992A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80510591A 1991-12-11 1991-12-11
US805105 1991-12-11

Publications (1)

Publication Number Publication Date
AU2981992A true AU2981992A (en) 1993-06-17

Family

ID=25190685

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29819/92A Abandoned AU2981992A (en) 1991-12-11 1992-12-02 Expression of specific immunogens using viral antigens

Country Status (17)

Country Link
US (1) US5591823A (enExample)
EP (1) EP0546787A3 (enExample)
JP (1) JPH05262667A (enExample)
KR (1) KR930013112A (enExample)
CN (1) CN1073878A (enExample)
AU (1) AU2981992A (enExample)
BR (1) BR9204978A (enExample)
CA (1) CA2084180A1 (enExample)
CZ (1) CZ362692A3 (enExample)
FI (1) FI925590A7 (enExample)
HU (2) HUT65366A (enExample)
IL (1) IL103928A0 (enExample)
MX (1) MX9207113A (enExample)
NO (1) NO924780L (enExample)
SK (1) SK362692A3 (enExample)
TW (1) TW239162B (enExample)
ZA (1) ZA929355B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633929B1 (en) * 1992-04-01 2004-03-03 The Rockefeller University METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS
DE69332485T2 (de) * 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
WO1995007099A1 (en) * 1993-09-09 1995-03-16 The Nisshin Oil Mills, Ltd. Vaccine and process for producing the same
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
EP1275726B1 (en) * 1995-05-26 2008-02-20 Mg-Pmc, L.L.C. A method for producing influenza hemagglutinin multivalent vaccines
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
WO1998048834A1 (en) * 1997-04-30 1998-11-05 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
DE69840739D1 (de) 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
JP2002504322A (ja) 1998-02-20 2002-02-12 ザ ロックフェラー ユニバーシティー 樹状細胞に対するアポトーシス細胞介在抗原提示
WO2002026252A1 (en) * 2000-08-10 2002-04-04 Tsinghua University A vaccine for influenza virus and its preparation
KR100836520B1 (ko) 2000-09-11 2008-06-12 다우 글로벌 테크놀로지스 인크. 무공압 주행 타이어 지지부
US20040203084A1 (en) * 2003-04-10 2004-10-14 Doug Levinson Profiling conformational variants, antibody compositions and methods of using the same
CA2610667A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2976814C (en) * 2007-08-27 2022-12-13 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods for treating influenza
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010047062A1 (en) 2008-10-22 2010-04-29 Oncotherapy Science, Inc. Rab6kifl/kif20a epitope peptide and vaccines containing the same
CN101708442B (zh) * 2009-09-04 2011-08-24 山东中惠仪器有限公司 全自动标准气体配制装置
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3411712B1 (en) * 2016-02-03 2025-11-19 CG Discovery, Inc. Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
EP0492920A1 (en) * 1990-12-24 1992-07-01 Merck & Co. Inc. Chimaeric influenza-HIV vaccine

Also Published As

Publication number Publication date
CN1073878A (zh) 1993-07-07
CZ362692A3 (en) 1994-02-16
NO924780D0 (no) 1992-12-10
NO924780L (no) 1993-06-14
JPH05262667A (ja) 1993-10-12
ZA929355B (en) 1994-06-02
EP0546787A3 (en) 1994-06-01
FI925590L (fi) 1993-06-12
MX9207113A (es) 1994-05-31
SK362692A3 (en) 1995-11-08
HU211548A9 (en) 1995-12-28
HUT65366A (en) 1994-05-02
BR9204978A (pt) 1993-06-15
FI925590A0 (fi) 1992-12-09
TW239162B (enExample) 1995-01-21
EP0546787A2 (en) 1993-06-16
IL103928A0 (en) 1993-04-04
FI925590A7 (fi) 1993-06-12
US5591823A (en) 1997-01-07
HU9203931D0 (en) 1993-04-28
CA2084180A1 (en) 1993-06-12
KR930013112A (ko) 1993-07-21

Similar Documents

Publication Publication Date Title
AU2981992A (en) Expression of specific immunogens using viral antigens
PL324906A1 (en) Vaccines against viral hepatitis of c type
AU1190688A (en) Silane microemulsions
AU625613B2 (en) Novel chimeric antibodies
AU4733989A (en) Gene family of tumor-associated antigens
AU1489188A (en) Novel vaccines
AU8604291A (en) Process for the preparation of carebastine
AU2370592A (en) Epitopes of the env protein of the hepatitis c virus
AU4212789A (en) Cloned nephritis antigen
AU2187788A (en) Antimalaria vaccines
AU8036291A (en) Process for the preparation of 1-hydroxymethylpyrazoles
AU2347692A (en) Recombinant viral vaccine
AU1820692A (en) Novel anti-hiv antibodies
AU5959494A (en) Vaccines against sterols
AU565485B2 (en) Supported viral antigen
AU8537091A (en) Membrane-derived antiflea vaccines
AU3432389A (en) Human monoclonal antibodies against rabies virus
AU7453687A (en) Novel vaccines
AU4080485A (en) Activated hbsag vaccine
AU5873094A (en) Multivalent ab1 antibodies as vaccines
AU8114891A (en) Process for the preparation of n-alkylsulfonylaminosulfonylureas
AU645182B2 (en) Process for the preparation of N-alkylsufonamides
AU5217890A (en) Monoclonal antibodies in vaccine formulations
AU7862291A (en) Modified antibodies
ZA94740B (en) Expression of pretective antigens